These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38897445)

  • 1. PIK3IP1: structure, aberration, function, and regulation in diseases.
    Jia Y; He P; Ma X; Lv K; Liu Y; Xu Y
    Eur J Pharmacol; 2024 Aug; 977():176753. PubMed ID: 38897445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma.
    He X; Zhu Z; Johnson C; Stoops J; Eaker AE; Bowen W; DeFrances MC
    Cancer Res; 2008 Jul; 68(14):5591-8. PubMed ID: 18632611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein.
    Zhu Z; He X; Johnson C; Stoops J; Eaker AE; Stoffer DS; Bell A; Zarnegar R; DeFrances MC
    Biochem Biophys Res Commun; 2007 Jun; 358(1):66-72. PubMed ID: 17475214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway.
    Song HK; Kim J; Lee JS; Nho KJ; Jeong HC; Kim J; Ahn Y; Park WJ; Kim DH
    PLoS One; 2015; 10(3):e0122251. PubMed ID: 25826393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity.
    Chen Y; Wang J; Wang X; Li X; Song J; Fang J; Liu X; Liu T; Wang D; Li Q; Wen S; Ma D; Xia J; Luo L; Zheng SG; Cui J; Zeng G; Chen L; Cheng B; Wang Z
    Clin Cancer Res; 2019 Oct; 25(20):6180-6194. PubMed ID: 31350312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of T-cell activation by PIK3IP1.
    DeFrances MC; Debelius DR; Cheng J; Kane LP
    Eur J Immunol; 2012 Oct; 42(10):2754-9. PubMed ID: 22706993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications.
    Xie W; Fang J; Shan Z; Guo J; Liao Y; Zou Z; Wang J; Wen S; Yang L; Zhang Y; Lu H; Zhao H; Kuang DM; Huang P; Chen Q; Wang Z
    Sci Adv; 2022 Sep; 8(39):eabo4250. PubMed ID: 36179018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3IP1/TrIP restricts activation of T cells through inhibition of PI3K/Akt.
    Uche UU; Piccirillo AR; Kataoka S; Grebinoski SJ; D'Cruz LM; Kane LP
    J Exp Med; 2018 Dec; 215(12):3165-3179. PubMed ID: 30429249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3IP1 Promotes Extrafollicular Class Switching in T-Dependent Immune Responses.
    Ottens K; Schneider J; Kane LP; Satterthwaite AB
    J Immunol; 2020 Oct; 205(8):2100-2108. PubMed ID: 32887751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.
    Lei K; Liang R; Liang J; Lu N; Huang J; Xu K; Tan B; Wang K; Liang Y; Wang W; Lin H; Wang M
    J Exp Clin Cancer Res; 2024 Apr; 43(1):124. PubMed ID: 38658954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Ischemic Effects of PIK3IP1 Are Mediated through Its Interactions with the ET
    Park JH; Nho KJ; Lee JY; Yoo YJ; Park WJ; Cho C; Kim DH
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
    Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
    Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RiPerC Attenuates Cerebral Ischemia Injury through Regulation of miR-98/PIK3IP1/PI3K/AKT Signaling Pathway.
    Zhang D; Mei L; Long R; Cui C; Sun Y; Wang S; Xia Z
    Oxid Med Cell Longev; 2020; 2020():6454281. PubMed ID: 33082912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.
    Joshi S; Wei J; Bishopric NH
    Biochim Biophys Acta; 2016 Feb; 1862(2):240-51. PubMed ID: 26655604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of PRIP, a phosphatidylinositol 4,5-bisphosphate binding protein, attenuates PI3K/AKT signaling and suppresses tumor growth in a xenograft mouse model.
    Maetani Y; Asano S; Mizokami A; Yamawaki Y; Sano T; Hirata M; Irifune M; Kanematsu T
    Biochem Biophys Res Commun; 2021 May; 552():106-113. PubMed ID: 33743346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRP94 promotes muscle differentiation by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li S; Fu Y; Pang Y; Tong H; Li S; Yan Y
    J Cell Physiol; 2019 Nov; 234(11):21211-21223. PubMed ID: 31025379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of forkhead box protein P1 alleviates hypoxia reoxygenation injury in H9c2 cells through regulating Pik3ip1/Akt/eNOS and ROS/mPTP pathway.
    Liu X; Yang Y; Song J; Li D; Liu X; Li C; Ma Z; Zhong J; Wang L
    Bioengineered; 2022 Jan; 13(1):1320-1334. PubMed ID: 35000528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Ras-LSD1 axis activates PI3K signaling through PIK3IP1 suppression.
    Lee K; Kitagawa M; Liao PJ; Virshup DM; Lee SH
    Oncogenesis; 2020 Jan; 9(1):2. PubMed ID: 31900384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
    Luo J; Cantley LC
    Cell Cycle; 2005 Oct; 4(10):1309-12. PubMed ID: 16131837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PIK3IP1 in the murine uterus during early pregnancy.
    Teasley HE; Chang HJ; Kim TH; Ku BJ; Jeong JW
    Biochem Biophys Res Commun; 2018 Jan; 495(4):2553-2558. PubMed ID: 29289536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.